Teva lowers full-year 2012 forecasts
Israel-based generic drug major Teva Pharmaceutical Industries (Nasdaq: TEVA) has provided its current outlook for non-GAAP financial performance for the full year ending December 31, 2012.
The company says it now expects total net sales of approximately $20 billion-$21 billion, down from a previous forecast of $22 billion. consisting of total US net sales of $10.5 billion, total European net sales of $5.8 billion, and total rest of the world net sales of $4.2 billion. Non-GAAP diluted earnings per share are now forecast to come in at between $5.30 and $5.40, down from previous projections of $5.48-$5.68, largely as a result of weaker economies and health care reform in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze